

# Mariaelena Pierobon

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8178736/publications.pdf>

Version: 2024-02-01

68  
papers

3,997  
citations

218677

26  
h-index

123424

61  
g-index

77  
all docs

77  
docs citations

77  
times ranked

9326  
citing authors

#	ARTICLE	IF	CITATIONS
1	The KRASG12C Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients. <i>Cancer Discovery</i> , 2020, 10, 54-71.	9.4	820
2	Combination of ERK and autophagy inhibition as a treatment approach for pancreatic cancer. <i>Nature Medicine</i> , 2019, 25, 628-640.	30.7	476
3	Obesity as a risk factor for triple-negative breast cancers: a systematic review and meta-analysis. <i>Breast Cancer Research and Treatment</i> , 2013, 137, 307-314.	2.5	281
4	Long-Term ERK Inhibition in KRAS-Mutant Pancreatic Cancer Is Associated with MYC Degradation and Senescence-like Growth Suppression. <i>Cancer Cell</i> , 2016, 29, 75-89.	16.8	191
5	A Portrait of Tissue Phosphoprotein Stability in the Clinical Tissue Procurement Process. <i>Molecular and Cellular Proteomics</i> , 2008, 7, 1998-2018.	3.8	187
6	Mechanism of Cell Adaptation. <i>Cancer Journal (Sudbury, Mass )</i> , 2011, 17, 89-95.	2.0	162
7	Laser capture microdissection technology. <i>Expert Review of Molecular Diagnostics</i> , 2007, 7, 647-657.	3.1	161
8	Atypical KRASG12R Mutant Is Impaired in PI3K Signaling and Macropinocytosis in Pancreatic Cancer. <i>Cancer Discovery</i> , 2020, 10, 104-123.	9.4	131
9	Multiplexed Cell Signaling Analysis of Human Breast Cancer Applications for Personalized Therapy. <i>Journal of Proteome Research</i> , 2008, 7, 1508-1517.	3.7	128
10	Molecular Analysis of HER2 Signaling in Human Breast Cancer by Functional Protein Pathway Activation Mapping. <i>Clinical Cancer Research</i> , 2012, 18, 6426-6435.	7.0	110
11	Gain-of-Function <i>RHOA</i> Mutations Promote Focal Adhesion Kinase Activation and Dependency in Diffuse Gastric Cancer. <i>Cancer Discovery</i> , 2020, 10, 288-305.	9.4	91
12	Lung Cancer Prognosis Before and After Recurrence in a Population-Based Setting. <i>Journal of the National Cancer Institute</i> , 2015, 107, djv059.	6.3	86
13	Reverse-phase protein microarrays: application to biomarker discovery and translational medicine. <i>Expert Review of Molecular Diagnostics</i> , 2007, 7, 625-633.	3.1	77
14	Enrichment of PI3K-AKT-mTOR Pathway Activation in Hepatic Metastases from Breast Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 4919-4928.	7.0	74
15	A pilot study utilizing multi-omic molecular profiling to find potential targets and select individualized treatments for patients with previously treated metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2014, 147, 579-588.	2.5	73
16	Low-Dose Vertical Inhibition of the RAF-MEK-ERK Cascade Causes Apoptotic Death of KRAS Mutant Cancers. <i>Cell Reports</i> , 2020, 31, 107764.	6.4	69
17	Inhibition of AKT1 signaling promotes invasion and metastasis of non-small cell lung cancer cells with K-RAS or EGFR mutations. <i>Scientific Reports</i> , 2017, 7, 7066.	3.3	68
18	Lessons from the Ebola Outbreak: Action Items for Emerging Infectious Disease Preparedness and Response. <i>EcoHealth</i> , 2016, 13, 200-212.	2.0	64

#	ARTICLE	IF	CITATIONS
19	Protein pathway biomarker analysis of human cancer reveals requirement for upfront cellular-enrichment processing. <i>Laboratory Investigation</i> , 2010, 90, 787-796.	3.7	59
20	Reverse Phase Protein Microarrays. <i>Methods in Molecular Biology</i> , 2017, 1606, 149-169.	0.9	55
21	Multiplexed Cell Signaling Analysis of Metastatic and Nonmetastatic Colorectal Cancer Reveals COX2-EGFR Signaling Activation as a Potential Prognostic Pathway Biomarker. <i>Clinical Colorectal Cancer</i> , 2009, 8, 110-117.	2.3	49
22	The Sustained Induction of c-MYC Drives Nab-Paclitaxel Resistance in Primary Pancreatic Ductal Carcinoma Cells. <i>Molecular Cancer Research</i> , 2019, 17, 1815-1827.	3.4	40
23	Impact of upfront cellular enrichment by laser capture microdissection on protein and phosphoprotein drug target signaling activation measurements in human lung cancer: Implications for personalized medicine. <i>Proteomics - Clinical Applications</i> , 2015, 9, 928-937.	1.6	32
24	Reverse-Phase Protein Microarrays. <i>Methods in Molecular Biology</i> , 2012, 823, 215-235.	0.9	30
25	Androgen Receptor Is a Non-canonical Inhibitor of Wild-Type and Mutant Estrogen Receptors in Hormone Receptor-Positive Breast Cancers. <i>IScience</i> , 2019, 21, 341-358.	4.1	29
26	Exploiting Radiation-Induced Signaling to Increase the Susceptibility of Resistant Cancer Cells to Targeted Drugs: AKT and mTOR Inhibitors as an Example. <i>Molecular Cancer Therapeutics</i> , 2018, 17, 355-367.	4.1	27
27	Integrated multi-omics analyses on patient-derived CRC organoids highlight altered molecular pathways in colorectal cancer progression involving PTEN. <i>Journal of Experimental and Clinical Cancer Research</i> , 2021, 40, 198.	8.6	27
28	Concurrent Inhibition of IGF1R and ERK Increases Pancreatic Cancer Sensitivity to Autophagy Inhibitors. <i>Cancer Research</i> , 2022, 82, 586-598.	0.9	27
29	Functional signaling pathway analysis of lung adenocarcinomas identifies novel therapeutic targets for KRAS mutant tumors. <i>Oncotarget</i> , 2015, 6, 32368-32379.	1.8	25
30	Functional characterization of epithelial ovarian cancer histotypes by drug target based protein signaling activation mapping: Implications for personalized cancer therapy. <i>Proteomics</i> , 2015, 15, 365-373.	2.2	22
31	A pilot study exploring the molecular architecture of the tumor microenvironment in human prostate cancer using laser capture microdissection and reverse phase protein microarray. <i>Molecular Oncology</i> , 2016, 10, 1585-1594.	4.6	21
32	Protein pathway activation mapping of colorectal metastatic progression reveals metastasis-specific network alterations. <i>Clinical and Experimental Metastasis</i> , 2013, 30, 309-316.	3.3	20
33	Extensive three-dimensional intratumor proteomic heterogeneity revealed by multiregion sampling in high-grade serous ovarian tumor specimens. <i>IScience</i> , 2021, 24, 102757.	4.1	20
34	Acquired small cell lung cancer resistance to Chk1 inhibitors involves Wee1 up-regulation. <i>Molecular Oncology</i> , 2021, 15, 1130-1145.	4.6	18
35	Reverse Phase Protein Microarrays for Clinical Applications. <i>Methods in Molecular Biology</i> , 2011, 785, 3-12.	0.9	17
36	Utilization of Proteomic Technologies for Precision Oncology Applications. <i>Cancer Treatment and Research</i> , 2019, 178, 171-187.	0.5	15

#	ARTICLE	IF	CITATIONS
37	The KRAS-regulated kinome identifies WEE1 and ERK coinhibition as a potential therapeutic strategy in KRAS-mutant pancreatic cancer. <i>Journal of Biological Chemistry</i> , 2021, 297, 101335.	3.4	14
38	CHK1 protects oncogenic KRAS-expressing cells from DNA damage and is a target for pancreatic cancer treatment. <i>Cell Reports</i> , 2021, 37, 110060.	6.4	14
39	Patient-derived xenografts of central nervous system metastasis reveal expansion of aggressive minor clones. <i>Neuro-Oncology</i> , 2020, 22, 70-83.	1.2	12
40	Regulation of Chemosensitivity in Human Medulloblastoma Cells by p53 and the PI3 Kinase Signaling Pathway. <i>Molecular Cancer Research</i> , 2022, 20, 114-126.	3.4	11
41	Protein Pathway Activation Associated with Sustained Virologic Response in Patients with Chronic Hepatitis C Treated with Pegylated Interferon (PEG-IFN) and Ribavirin (RBV). <i>Journal of Proteome Research</i> , 2011, 10, 774-779.	3.7	10
42	Reverse Phase Protein Microarrays and Their Utility in Drug Development. <i>Methods in Molecular Biology</i> , 2013, 986, 187-214.	0.9	10
43	Phosphorylation, Signaling, and Cancer: Targets and Targeting. <i>BioMed Research International</i> , 2015, 2015, 1-3.	1.9	10
44	Kinase-driven metabolic signalling as a predictor of response to carboplatin+paclitaxel adjuvant treatment in advanced ovarian cancers. <i>British Journal of Cancer</i> , 2017, 117, 494-502.	6.4	10
45	Stratification of clear cell renal cell carcinoma by signaling pathway analysis. <i>Expert Review of Proteomics</i> , 2014, 11, 237-249.	3.0	9
46	The impact of ultraviolet- and infrared-based laser microdissection technology on phosphoprotein detection in the laser microdissection-reverse phase protein array workflow. <i>Clinical Proteomics</i> , 2020, 17, 9.	2.1	9
47	Concurrent Inhibition of ERK and Farnesyltransferase Suppresses the Growth of HRAS Mutant Head and Neck Squamous Cell Carcinoma. <i>Molecular Cancer Therapeutics</i> , 2022, 21, 762-774.	4.1	9
48	P2RY2-AKT activation is a therapeutically actionable consequence of XPO1 inhibition in acute myeloid leukemia. <i>Nature Cancer</i> , 2022, 3, 837-851.	13.2	9
49	An exploratory study examining how nano-liquid chromatography+mass spectrometry and phosphoproteomics can differentiate patients with advanced fibrosis and higher percentage collagen in non-alcoholic fatty liver disease. <i>BMC Medicine</i> , 2018, 16, 170.	5.5	8
50	Endogenous Gastrin Collaborates With Mutant KRAS in Pancreatic Carcinogenesis. <i>Pancreas</i> , 2019, 48, 894-903.	1.1	8
51	Protein drug target activation homogeneity in the face of intra-tumor heterogeneity: implications for precision medicine. <i>Oncotarget</i> , 2017, 8, 48534-48544.	1.8	7
52	Multiplexed Protein Signal Pathway Mapping Identifies Patients With Rectal Cancer That Responds to Neoadjuvant Treatment. <i>Clinical Colorectal Cancer</i> , 2012, 11, 268-274.	2.3	6
53	Multi-omic molecular profiling guide™s efficacious treatment selection in refractory metastatic breast cancer: a prospective phase II clinical trial. <i>Molecular Oncology</i> , 2022, 16, 104-115.	4.6	6
54	Reverse phase protein array (RPPA) combined with computational analysis to unravel relevant prognostic factors in non-small cell lung cancer (NSCLC): a pilot study. <i>Oncotarget</i> , 2017, 8, 83343-83353.	1.8	6

#	ARTICLE	IF	CITATIONS
55	PD-L1 quantification across tumor types using the reverse phase protein microarray: implications for precision medicine. , 2021, 9, e002179.		6
56	Protein network construction using reverse phase protein array data. <i>Methods</i> , 2017, 124, 89-99.	3.8	5
57	Phosphoprotein-based drug target activation mapping for precision oncology: a view to the future. <i>Expert Review of Proteomics</i> , 2018, 15, 851-853.	3.0	3
58	Wild-Type KRAS Allele Effects on Druggable Targets in KRAS Mutant Lung Adenocarcinomas. <i>Genes</i> , 2021, 12, 1402.	2.4	3
59	Selinexor in Combination with Induction and Consolidation Therapy in Older Adults with AML Is Highly Active. <i>Blood</i> , 2019, 134, 1388-1388.	1.4	3
60	Multi-omic profiling of metastatic lesions to guide treatment selection: The Side Out 2 trial experience.. <i>Journal of Clinical Oncology</i> , 2018, 36, 1077-1077.	1.6	3
61	Alcohol consumption and violence among Argentine adolescents. <i>Jornal De Pediatria (Versão Em Tj ETQq1 1 0.784314 rgBT<sub>2</sub> /Overlock</i>	0.2	
62	Heterogeneous Off-Target Effects of Ultra-Low Dose Dimethyl Sulfoxide (DMSO) on Targetable Signaling Events in Lung Cancer In Vitro Models. <i>International Journal of Molecular Sciences</i> , 2021, 22, 2819.	4.1	1
63	Integrated multi-omic analyses reveals clinical relevance of endometrial cancer cell line models. <i>Gynecologic Oncology</i> , 2021, 162, S11.	1.4	1
64	Applications of Proteomics to Metastasis Diagnosis and Individualized Therapy. , 0, , 475-485.		0
65	Integration of Protein Network Activation Mapping Technology for Personalized Therapy. , 2014, , 367-383.		0
66	The AKT-mTOR Signaling Pathway for Drug Response Prediction and Prognostic Signatures. <i>Cancer Drug Discovery and Development</i> , 2016, , 109-124.	0.4	0
67	Network-based analysis of reverse phase protein array data. , 2016, , .		0
68	MA04.06 Signaling Networks in KRAS-Mutant Advanced NSCLC: A Complex Landscape Involving Immunoreponse, Inflammation and DNA Repair. <i>Journal of Thoracic Oncology</i> , 2017, 12, S360-S361.	1.1	0